Personalised Cancer Plan
Make treatment decisions with greater confidence
Precision insights that complement standard oncology care to guide next-step planning and ongoing monitoring.
Precision medicine strengthens conventional cancer care by integrating molecular and biological insights to support more informed treatment strategies.
In recurrent ovarian cancer, biomarker-guided chemotherapy significantly improved clinical outcomes — increasing response rates from 5% to 55% and extending progression-free intervals from 3 to 11 months.
Across matched therapy approaches, clinical improvements have included:
- Response rates increased from 5% to 12%
- Progression-free survival extended from 2 to 4 months
- Overall survival improved from 8.6 to 11.4 months
How Precision Medicine Supports Your Treatment Options
Understanding your cancer at a biological level may help guide more informed treatment selection and sequencing.
Traditional Approach
Diagnosis
Treatment based on guidelines
Treatment begins
Imaging & clinical review
Doctor evaluates response
Adjust or change treatment
Based on imaging response
Decisions mainly guided by clinical & imaging findings.
Precision Medicine–Guided Approach
Diagnosis
Clinical evaluation + biological assessment
Integrated treatment planning
Treatment begins with monitoring
Doctor evaluates response
Imaging + biological signals
Treatment adjusted using complete information
Biological data supports sequencing and decision-making.
Are you starting your Chemo?
Get a free 15 min discussion with our expert
Empower yourself with knowledge about precision medicine!
Matched vs Non-Matched Therapy Outcomes
Response Rate (%)
PFS (months)
Overall Survival (months)
Chemotherapy as an Example
Precision approaches may help guide chemotherapy selection and monitoring.
CTC vs ctDNA — Different but Complementary Insights
ctDNA (Circulating Tumour DNA)
- ✓ Detects genetic mutations
- ✓ Tracks tumour genetic evolution
- ✓ Useful for mutation monitoring over time
- ✕ Does not provide whole viable cancer cells
CTCs (Circulating Tumour Cells)
- ✓ Provides whole cancer cells for analysis
- ✓ Enables functional drug sensitivity testing
- ✓ Predicts survival across multiple solid tumours
- ✕ Not primarily used for detailed mutation tracking
Based on Alix-Panabières & Pantel, Nature Reviews Clinical Oncology (2016).
Monitoring Cancer Over Time
References
| # | Study | Year | Key Findings |
|---|---|---|---|
| 6 | Tsimberidou AM et al. Personalized medicine for patients with advanced cancer in phase I program at MD Anderson. | 2014 | Response 12% vs 5%; PFS 4 vs 2 months; OS 11 vs 9 months. |
| 7 | IMPACT Study – MD Anderson Precision Medicine Program. | 2017 | Matched therapy associated with improved response and survival outcomes. |
| 8 | UCSD Moores Cancer Center PREDICT Study. | 2016 | Stable disease or better 35% vs 16%; prolonged time without progression. |
| 9 | Real-world Molecular Tumor Board Data in Breast & Gynecologic Cancers. | 2022 | Response 31% vs 7%; reduced progression risk. |
| 10 | Herzog TJ et al. ChemoID-guided therapy in platinum-resistant ovarian cancer. | 2025 | ORR 55% vs 5%; PFS 11 vs 3 months (HR 0.27). |
| 11 | Tsimberidou AM et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT). JCO. | 2012 | Matched therapy improved response rates and survival compared to non-matched. |
| 12 | Von Hoff DD et al. Pilot study using molecular profiling to select therapy. JCO. | 2010 | Targeted treatment improved progression-free survival compared to prior therapy. |
| 13 | Alix-Panabières C, Pantel K. Clinical relevance of circulating tumor cells and ctDNA. Nat Rev Clin Oncol. | 2016 | CTCs predict survival across solid tumors; ctDNA useful for mutation tracking. |
| 14 | Pediatric MATCH Trial (National Cancer Institute). | 2020 | 2-year PFS 26% vs 12% in selected molecularly matched pediatric cases. |
| 15 | MD Anderson IMPACT Long-term Follow-up Analysis. | 2019 | Matched targeted therapy associated with improved overall survival. |
For educational purposes only. Outcomes vary based on tumor biology, disease stage, prior treatments, and individual patient factors.
Are you starting your Chemo?
Get a free 15 min discussion with our expert
Empower yourself with knowledge about precision medicine!
Contact Us
Contact Us for the updated information on Precision Medicine
+852 4750 3485
Email Us
info@mycancerinfo.org